Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.713 EUR | -32.98% |
|
0.00% | 0.00% |
Jul. 11 | Deutsche Bank downgrades Evotec to 'Hold' - annual targets at risk | DP |
Jul. 11 | EVOTEC : Deutsche Bank is less optimistic | ZD |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 48% by 2026.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 1.67B | - | ||
+25.83% | 47.96B | B- | ||
+45.38% | 41.47B | A | ||
+0.69% | 42.45B | B | ||
+30.52% | 31.6B | B | ||
+22.30% | 28.63B | B- | ||
-6.35% | 28.03B | C | ||
+49.25% | 14.56B | B+ | ||
+49.18% | 14.14B | C+ | ||
+3.45% | 12.58B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EVT Stock
- EVT Stock
- Ratings Evotec